CRP and rheumatoid arthritis: As described for RA, despite improvement of disease activity assessed with BASDAI (Figure 1B) or ASDAS-CRP (Figure 1C) and disability evaluated with BASFI (Figure 1D), no significant correlation was observed between sGal1 levels and BASDAI, ASDAS or BASFI (Figure 1E–G).